A groundbreaking gene-editing therapy has given new hope to families battling rare genetic diseases. In a landmark case, doctors at Children's Hospital of Philadelphia and Penn Medicine created a personalized CRISPR treatment for KJ Muldoon, a baby born with a severe enzyme deficiency that affects one in 1.3 million newborns.

Using mRNA technology similar to Covid-19 vaccines, the team designed a therapy to correct a single misspelled letter in KJ's DNA. The six-month development process compressed years of research into months, with the FDA granting authorization just one week after application submission. One year later, KJ is thriving at home, walking and talking normally.

The economics of rare disease treatment have long been prohibitive, with fewer than five percent of conditions having FDA-approved therapies despite affecting 25 million Americans and costing an estimated $400 billion annually. This breakthrough demonstrates how mRNA-CRISPR technology could be reprogrammed for different diseases by changing a single piece of genetic code.